Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generics proposal pulled

This article was originally published in The Tan Sheet

Executive Summary

FDA withdraws Aug. 6, 1999 proposed rule on 180-day generic exclusivity and ANDA approvals "in light of [court] decisions" invalidating agency's position on which rulings in patent infringement suits can trigger 180-day period. Proposal stated FDA would not start the clock until after a court decision from which no appeal could be taken, but a January 2000 D.C. federal court concluded 180 days was triggered by trial court decision on patent invalidity. Agency's most recent Hatch/Waxman proposed rule does not discuss the 180-day provision (1"The Tan Sheet" Oct. 28, 2002, p. 10). FDA will "carefully evaluate possible options for future rulemaking addressing 180-day exclusivity and the timing of ANDA approvals," agency says in 2Nov. 1 Federal Register notice...

You may also be interested in...

Hatch/Waxman Reinterpretation Underpins Change In 30-Month Stay Policy

FDA's proposal to allow only one 30-month stay of approval for ANDAs hinges on a reinterpretation of Hatch/Waxman language declaring that patent holders must be notified if a generic application is amended to "include" a Paragraph IV certification

QUOTED. 9 April 2020. Frans van Houten.

Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.

COVID-19 Lock-Down: India Pharma Manufacturing Limps Along Amid Challenges

Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts